Johnson & Johnson (NYSE:JNJ) Stock Falls 2.1% – Here’s Why

Johnson & Johnson (NYSE:JNJ – Get Free Report) shares dropped 2.1% during trading on Thursday. The company traded as low as $264.68 and last traded at $267.02. 9,825,683 shares were traded during mid-day trading, an increase of 24% from the average daily volume of 7,955,000 shares. The stock had previously closed at $272.70.

More Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Evercore set a $300.00 target price on shares of Johnson & Johnson in a report on Tuesday, October 20th. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Guggenheim reissued a “buy” rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Finally, UBS Group set a $270.00 price objective on Johnson & Johnson in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Check Out Our Latest Report on JNJ

Johnson & Johnson Stock Performance

The stock has a market capitalization of $642.80 billion, a price-to-earnings ratio of 40.46, a P/E/G ratio of 2.75 and a beta of 0.22. The company’s fifty day simple moving average is $267.42 and its 200 day simple moving average is $250.61. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. During the same quarter last year, the company posted $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 81.21%.

Insider Activity at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. The trade was a 43.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently modified their holdings of the company. Heartland Bank & Trust Co grew its stake in shares of Johnson & Johnson by 0.8% in the third quarter. Heartland Bank & Trust Co now owns 15,295 shares of the company’s stock valued at $4,049,000 after acquiring an additional 118 shares in the last quarter. Kensington Investment Counsel LLC raised its stake in Johnson & Johnson by 3.6% in the 3rd quarter. Kensington Investment Counsel LLC now owns 26,582 shares of the company’s stock worth $7,037,000 after purchasing an additional 919 shares in the last quarter. Robinhood Markets Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $282,000. Innovator Capital Management LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at about $35,454,000. Finally, Claris Financial LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at about $1,245,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Recommended Stories

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.